Video

Dr. Scarpato highlights case-based discussion on intermediate-risk NMIBC

Author(s):

Urology Times staff
Conference|SUO Annual Meeting

“[I focused on] why this such an important topic and how we might better counsel our patients,” says Kristen Scarpato, MD, MPH.

In this video, Kristen Scarpato, MD, MPH, discusses key points of a case-based discussion on intermediate-risk non-muscle invasive bladder cancer taking place during the 2021 Society of Urologic Oncology Annual Meeting. Scarpato is an associate professor, residency program director, and vice chair of education in the department of urology at the Vanderbilt University Medical Center in Nashville, Tennessee.

Related Videos
William Furuyama, MD, answers a question during a Zoom video interview
Related Content
ARANOTE substudy highlights benefits of darolutamide in Black men
April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Skyler Howell, MD | Credit: X.com
April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell
New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.
Pearls & Perspectives: Urology's Role in GLP-1 RA Treatments, with Hossein Sadeghi-Nejad, MD, and Nathalie Eid, BA | Credit: Urology Times
April 28th 2025

Pearls & Perspectives: Urology's role in GLP-1 RA treatments, with Hossein Sadeghi-Nejad, MD, and Nathalie Eid, BA

Amy M. Pearlman, MD Hossein Sadeghi-Nejad, MD Nathalie Eid, BA
This episodes explores the evolving role of GLP-1 medications in testosterone management and their impact on male sexual health and fertility.
Stephen J. Freedland, MD
April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor
More than 80% of patients in both groups had a full recovery of testosterone.
Sandip M. Prasad, MD, MPhil
April 27th 2025

UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

Benjamin P. Saylor
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
© 2025 MJH Life Sciences

All rights reserved.